Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-21
2008-08-05
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07407973
ABSTRACT:
The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
REFERENCES:
patent: 3547119 (1970-12-01), Hall
patent: 3760984 (1973-09-01), Theeuwes
patent: 3839346 (1974-10-01), Gadekar
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3923426 (1975-12-01), Theeuwes
patent: 3974281 (1976-08-01), Gadekar
patent: 3987790 (1976-10-01), Eckenhoff et al.
patent: 3995631 (1976-12-01), Higuchi et al.
patent: 4016880 (1977-04-01), Theeuwes et al.
patent: 4036228 (1977-07-01), Theeuwes
patent: 4042699 (1977-08-01), Gadekar
patent: 4052509 (1977-10-01), Gadekar
patent: 4111202 (1978-09-01), Theeuwes
patent: 4111203 (1978-09-01), Theeuwes
patent: 4203440 (1980-05-01), Theeuwes
patent: 4203442 (1980-05-01), Michaels
patent: 4210139 (1980-07-01), Higuchi
patent: 4311137 (1982-01-01), Gerard
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4350155 (1982-09-01), Thompson
patent: 4360019 (1982-11-01), Portner et al.
patent: 4487603 (1984-12-01), Harris
patent: 4531937 (1985-07-01), Yates
patent: 4627850 (1986-12-01), Deters et al.
patent: 4692147 (1987-09-01), Duggan
patent: 4695623 (1987-09-01), Stabinsky
patent: 4725852 (1988-02-01), Gamblin et al.
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4755173 (1988-07-01), Konopka et al.
patent: 4810804 (1989-03-01), Chandraratna
patent: 4865845 (1989-09-01), Eckenhoff et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5057318 (1991-10-01), Magruder et al.
patent: 5059423 (1991-10-01), Magruder et al.
patent: 5112614 (1992-05-01), Magruder et al.
patent: 5137727 (1992-08-01), Eckenhoff
patent: 5200534 (1993-04-01), Rao
patent: 5229529 (1993-07-01), Ueno et al.
patent: 5234692 (1993-08-01), Magruder et al.
patent: 5234693 (1993-08-01), Magruder et al.
patent: 5274137 (1993-12-01), Nicolaou et al.
patent: 5279949 (1994-01-01), Nair
patent: 5283253 (1994-02-01), Holton et al.
patent: 5294637 (1994-03-01), Chen et al.
patent: 5310562 (1994-05-01), Margolin
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5399586 (1995-03-01), Davies et al.
patent: 5415869 (1995-05-01), Straubinger et al.
patent: 5443450 (1995-08-01), Kratoska et al.
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5518729 (1996-05-01), Margolin
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5643207 (1997-07-01), Rise
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5690925 (1997-11-01), Gray et al.
patent: 5716632 (1998-02-01), Margolin
patent: 5728396 (1998-03-01), Peery et al.
patent: 5770378 (1998-06-01), Hwang et al.
patent: 5770382 (1998-06-01), Hwang et al.
patent: 5770383 (1998-06-01), Hwang et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 5814019 (1998-09-01), Steinbach et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5821263 (1998-10-01), Scola et al.
patent: 5824685 (1998-10-01), Campochiaro et al.
patent: 5824701 (1998-10-01), Greenwald et al.
patent: 5869680 (1999-02-01), Mas et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 5962478 (1999-10-01), Margolin
patent: 5976109 (1999-11-01), Heruth
patent: 5981709 (1999-11-01), Greenwald et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 5985305 (1999-11-01), Peery et al.
patent: 6017328 (2000-01-01), Fischell et al.
patent: 6046305 (2000-04-01), Choi
patent: 6090822 (2000-07-01), Margolin
patent: 6171276 (2001-01-01), Lippe et al.
patent: 6198966 (2001-03-01), Heruth
patent: 6214542 (2001-04-01), Striker et al.
patent: 6214854 (2001-04-01), Wang et al.
patent: 6241704 (2001-06-01), Peterson et al.
patent: 6300349 (2001-10-01), Margolin
patent: 6464687 (2002-10-01), Ishikawa et al.
patent: 6475180 (2002-11-01), Peterson et al.
patent: 6489325 (2002-12-01), Adams et al.
patent: 6492395 (2002-12-01), Scheiwe et al.
patent: 6497871 (2002-12-01), Gray et al.
patent: 6512954 (2003-01-01), Fox et al.
patent: 6541447 (2003-04-01), Dawson
patent: 6548520 (2003-04-01), Adams et al.
patent: 6569871 (2003-05-01), Adams et al.
patent: 6579856 (2003-06-01), Mercola
patent: 6680335 (2004-01-01), Tang
patent: 6943161 (2005-09-01), Erickson et al.
patent: 2001/0036955 (2001-11-01), Gerritsen et al.
patent: 2002/0156023 (2002-10-01), Walling et al.
patent: 590267 (2002-05-01), None
patent: WO 90/04036 (1990-04-01), None
patent: WO 90/10077 (1990-09-01), None
patent: WO 92/02190 (1992-02-01), None
patent: WO 93/10076 (1993-05-01), None
patent: WO 93/23555 (1993-11-01), None
patent: WO 94/07876 (1994-04-01), None
patent: WO 94/07880 (1994-04-01), None
patent: WO 94/07881 (1994-04-01), None
patent: WO 94/07882 (1994-04-01), None
patent: WO 97/03106 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 97/27840 (1997-08-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/22451 (1998-05-01), None
patent: WO 98/58927 (1998-12-01), None
patent: WO 99/09021 (1999-02-01), None
patent: WO 99/14209 (1999-03-01), None
patent: WO 99/18113 (1999-04-01), None
patent: WO 01/36001 (2001-05-01), None
Hawk et al., Primary Cancer Prevention Trials, Hematology/Oncology Clinics of North America, vol. 14, No. 4, Aug. 2000, pp. 809-830.
Cecil, Textbook of Medicine, 21st ed., vol. 1, published 2000 by W.B Saunders Company (PA), pp. 1060-1074.
Medline Abstract No. 97217050, Kumar, Indian Journal of Experimental Biology, (May 1996) 34(5), 391-402.
Medline Abstract No. 96432582, Oka et al., Japanese Journal of Pharmacology, (Jun. 1996) 71(2), 89-100.
Medline Abstract No. 97074593, Smith et al., CA: A Cancer Journal for Clinicians, (Nov.-Dec. 1996), 46(6), 343-363.
Medline Abstract No. 1998029329, Rickels et al., Journal of Clinical Psychiatry, (1997) 58 Suppl. 11, 4-10.
Auerbach et al., “Assays for Angiogenesis: A Review”, Pharmac. Ther., 51:1-11, 1991.
Baert et al., “Tumor Necrosis Factor α Antibody (Infliximab) Therapy Profoundly Down-regulates the Inflammation in Crohn's Ileocolitis”, Gastroenterology, 116:22-28, 1999.
Brunt, “Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond”, Hepatology, 31:241-246, 2000.
Chamow et al., “Modification of CD4 Immunoadhesin with Monomethoxypoly(ethylene glycol) Aldehyde via Reductive Alkylation”, Bioconj. Chem., 5:133-140, 1994.
Elliott et al., “Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α”, Arthritis Rheum., 36:1681-1690, 1993.
Elliott et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α(cA2) versus placebo in rheumatoid arthritis”, Lancet, 344:1105-1110, 1994.
Forrer et al., “Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 Kinase Activities”, Biol. Chem., 379:1101-1111, 1998.
Friedler et al., “Development of a functional backbone cyclic mimetic of the HIV-1 Tat Arginine-rich Motif”, J. Biol. Chem., 275:23783-23789, 2000.
Gray et al., “Expression of human immune interferon cDNA inE. coliand monkey
Blatt Lawrence M.
Ozes Osman N.
Seiwert Scott D.
Henley, III Raymond J
Intermune, Inc.
Marshall & Gerstein & Borun LLP
Tang Carolyn
LandOfFree
Use of pirfenidone in therapeutic regimens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of pirfenidone in therapeutic regimens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pirfenidone in therapeutic regimens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015525